Press Releases
PFIZER INITIATES PHASE 1 CLINICAL TRIAL FOR FVIIa HEMOPHILIA DRUG CANDIDATE DEVELOPED BY CATALYST BIOSCIENCES
South San Francisco, CA, January 5, 2012 - Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced that Pfizer Inc. has initiated a Phase 1 clinical trial for PF-05280602, an investigational proprietary, engineered variant of recombinant human Factor VIIa developed by Catalyst Biosciences. PF-05280602 has been engineered to provide improved acute and prophylactic treatment for hemophilia A & B patients with
inhibitors. The IND filing and initiation of the Phase 1 clinical trial triggered additional milestone payments of $7.0 million payable to Catalyst by Pfizer under the terms of their research and license agreement.
CATALYST BIOSCIENCES RECEIVES MILESTONE PAYMENT FROM PFIZER FOR PROGRESS IN LEAD HEMOSTATIS PROGRAM
South San Francisco, CA, December 16, 2010 - Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced the receipt of a $4.0 million milestone payment from Pfizer Inc. under the terms of the collaboration agreement for the development of improved recombinant human Factor VIIa variants for the treatment of hemophilia and other bleeding disorders.
CATALYST BIOSCIENCES ANNOUNCES AGREEMENT WITH MEDIMMUNE TO DISCOVER AND DEVELOP ENGINEERED PROTEASE THERAPEUTICS
South San Francisco, CA, July 7, 2009 - Catalyst Biosciences, Inc. today announced the signing of an exclusive worldwide research and license agreement with MedImmune, the global biologics unit of AstraZeneca plc, to develop novel engineered proteases that specifically degrade or modulate two targets, one of which will address inflammatory and autoimmune diseases.
CATALYST BIOSCIENCES AND WYETH PHARAMCEUTICALS ANNOUNCE WORLDWIDE COLLABORATION
Collegeville, PA and South San Francisco, CA, June 30, 2009 - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Catalyst Biosciences, Inc. today announced that the two companies have formed an exclusive worldwide collaboration for the discovery, development and commercialization of Factor VIIa products to treat hemophilia and other bleeding conditions. Total payments under the collaboration, including an upfront payment of $21 million, research funding and milestone payments, could exceed $500 million, exclusive of royalty payments.
CATALYST BIOSCIENCES EXPANDS SCIENTIFIC ADVISORY BOARD WITH LEADING EXPERTS IN PROTEASE THERAPEUTIC DISCOVERY AND DEVELOPMENT
South San Francisco, CA, March 24, 2009 - Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase™ therapeutics, has appointed four new members to the company’s Scientific Advisory Board (SAB). Robert J. Fletterick, Ph.D., David Ginsburg M.D., Guy S. Salvesen, Ph.D., and Gregory Stahl, Ph.D., join initial members Shaun Coughlin, M.D., Ph.D., Charles Craik, Ph.D., and James Wells, Ph.D.
CATALYST BIOSCIENCES RAISES $40 MILLION IN SERIES C FINANCING
South San Francisco, CA, December 3, 2008 - Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase™ therapeutics, has raised $40.4 million in a Series C financing round. New investor Essex Woodlands Health Ventures led the round, with participation from existing investors Burrill & Company, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures and Sofinnova Ventures. More»
CATALYST
BIOSCIENCES SELECTS DRUG DEVELOPMENT CANDIDATE IN FACTOR VIIA
PROGRAM FOR HEMOPHILIA
South
San Francisco, CA, May 6, 2008 - Catalyst
Biosciences, Inc., a pioneer in the discovery and development of
engineered proteases known as Alterase™ therapeutics, announced
that it has selected CB 813, an improved, second-generation variant
of human coagulation factor VIIa, as a development candidate
for the treatment of acute bleeding in hemophilia patients. More»
South San Francisco, CA, January 7, 2008 - Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase™ therapeutics, today announced that it has entered into an exclusive worldwide research and license agreement with Centocor Research & Development, Inc. More»
South San Francisco, CA, January 7, 2007 – Catalyst Biosciences, Inc., today announced that it has signed two research collaboration and license agreements with Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), having potential total payments of up to $100 million, exclusive of potential royalty payments. More »
CATALYST ANNOUNCES APPOINTMENT OF NASSIM USMAN AS CEO
South San Francisco, CA, February 22, 2006 – Catalyst Biosciences, Inc., a privately held biotechnology company focused on engineering and developing novel therapeutic protease products, today announced that Nassim Usman, Ph.D., has been named the Company's Chief Executive Officer. More »
CATALYST BIOSCIENCES RAISES $30 MILLION SERIES B FINANCING TO ADVANCE THERAPEUTIC PROTEASES
South San Francisco, CA, February 9, 2006 – Catalyst Biosciences, Inc., a privately held biotechnology company focused on engineering and developing novel therapeutic protease producs, today announced it has raised $30 million in its Series B financing. More »
CATALYST BIOSCIENCES LICENSES SEMINAL INTELLECTUAL PROPERTY IN THE FIELD OF PROTEASE THERAPEUTICS
South San Francisco, CA and San Diego, CA, July 25, 2005 – Catalyst Biosciences, Inc. and Torrey Pines Institute for Molecular Studies announced today that they have entered into an exclusive worldwide license agreement for Catalyst’s use of the Institute’s seminal intellectual property covering protease engineering, selection and optimization. More »
CATALYST
BIOSCIENCES RAISES $10 MILLION IN SERIES A FINANCING
October 28, 2004 - Catalyst Biosciences, Inc., a protein therapeutics company,
today announced that it has closed a Series A round of funding at $10.3 million.
Sofinnova Ventures led the financing, which also included Burrill and Company,
RCT Bioventures and Novartis Venture Fund. Catalyst will use the financing
to move its research and development programs through pre-clinical animal models
toward clinical development, to expand its technology and infrastructure platform,
and to add key personnel and laboratory space. More »
